Market Research Logo

Global Antifungal Market: Industry Analysis & Outlook (2016-2020)

Global Antifungal Market: Industry Analysis & Outlook (2016-2020)

Fungal infection is most common in those with weakened immune system or those who have foreign material, including medical devices in their body like an artificial joint or heart valve. Fungal infections are categorized under opportunistic and primary fungal infection. Opportunistic fungal infection targets weak immune patients and can be very aggressive, spreading quickly to other organs and often leading to death. While primary fungal infection can occur in people with a normal immune system. There are several types of antifungal medicines. They come in as creams, sprays, solutions, tablets designed to go into the vagina (pessaries), shampoos, medicines to take by mouth, and injections. Most work by damaging the cell wall of the fungus, which causes the fungal cell to die.

The US is the largest market of anti-fungal drugs. It has the presence of the leading companies who specialize in anti-fungal drugs. The key factors driving growth of the anti-fungal market include rise in incidences of fungal infections in immuno-compromised patients, increase in number of cancer patients, rise in incidences of fungal infections in people suffering from AIDS, increase in spending on medicines, rise in sale of prescription drugs and many more.

However, market growth is hindered by the factors such as harsh side effects of drugs, drug resistance, high cost of anti-fungal, and lack of new anti-fungal therapies. The major trends featuring the market include increase in development of new drugs, flourishing public-private partnership in pharmaceutical industry, and growing awareness.

The report offers an in-depth analysis of the “Global Anti-Fungal Market” with special focus on invasive anti-fungal segment. It covers the regional and global aspects of the market. The top notch players in the market exhibit a very close competition. The report profiles JNJ, Novartis, Pfizer, and Merck & Co.


1. Market Overview
1.1 Fungal Infection
Table A: Risk Factors for Developing Fungal Infections
1.2 Types of Fungal Infection
Table 1: Types of Fungal Infections
1.3 Treatment (Antifungal)
Table B: Drugs for Serious Fungal Infections
2. Global Antifungal Market
2.1 Global Antifungal Market by Value
Table 2: Global Anti-Fungal Market by Value (2011-2015)
2.2 Global Antifungal Market Forecast by Value
Table 3: Global Anti-Fungal Market Forecast by Value (2016-2020)
2.5 Global Antifungal Market by Region
Table 4: Global Anti-Fungal Market by Region (2015)
3. Global Invasive Antifungal Market
3.1 Global Invasive Anti-Fungal Market by Value
Table 5: Global Invasive Anti-Fungal Market by Value (2011-2015)
3.2 Global Invasive Anti-Fungal Market Forecast by Value
Table 6: Global Invasive Anti-Fungal Market Forecast by Value (2016-2020)
3.3 Global Invasive Anti-Fungal Market by Drug Class
Table 7: Global Invasive Anti-Fungal Market by Drug Class (2015)
3.4 Global Invasive Anti-Fungal Market by Major Drugs
Table 8: Global Invasive Anti-Fungal Market by Major Drugs (2015)
3.5 Global Invasive Anti-Fungal Market by Target Patients
Table 9: Global Invasive Anti-Fungal Market by Target Patients (2015)
3.6 Global Invasive Anti-Fungal Market by Therapeutic Indication
Table C: Global Invasive Anti-Fungal Market by Therapeutic Indication (2015)
4. Regional Anti-Fungal Market Analysis
4.1 The Americas
4.1.1 North America Anti-Fungal Market by Value
Table 10: North America Anti-Fungal Market by Value (2011-2015)
4.1.2 North America Anti-Fungal Market Forecast by Value
Table 11: North America Anti-Fungal Market Forecast by Value (2016-2020)
4.1.3 Latin & South America Anti-Fungal Market by Value
Table 12: Latin & South America Anti-Fungal Market by Value (2011-2015)
4.1.4 Latin & South America Anti-Fungal Market Forecast by Value
Table 13: Latin & South America Anti-Fungal Market Forecast by Value (2016-2020)
4.2 Europe
4.2.1 Europe Anti-Fungal Market by Value
Table 14: Europe Anti-Fungal Market by Value (2011-2015)
4.2.2 Europe Anti-Fungal Market Forecast by Value
Table 15: Europe Anti-Fungal Market Forecast by Value (2016-2020)
5. Market Dynamics
5.1 Recent Trends and Developments
5.1.1 Increase in Development of New Drugs
Table D: Development Progress of Anti-Fungal Drugs
5.1.2 Flourishing Public-Private Partnership
5.1.3 Growing Public Awareness
5.1.4 Rise in FDA Approvals
5.2 Growth Drivers
5.2.1 Rise in Incidences of Fungal Infections in Immuno-compromised Patients
Table E: Global Estimates of Fungal Infection in Immuno-Compromised Patients (2015)
5.2.2 Increasing Unhygienic Conditions in Developed Cities
5.2.3 Rise in fungal Infections in People Suffering from AIDS
Table F: Global Estimates and Related Deaths of Fungal Infection per Year among People With AIDs
5.2.4 Increase in Number of Cancer Patients
Table 16: Global New Cancer Patients by Volume (2011-2015)
5.2.5 Increasing Sales of Prescription Drugs
Table 17: Increase in Sales of Prescription Drugs (2010-2015)
5.2.6 Increased Spending on Medicines
Table 18: Global Spending on Medicines (2010-2020E)
Table 19: Total Spending on Medicines in the US (2010-2015)
5.2.7 Increasing Global Healthcare Expenditure
Table 20: Global Healthcare Expenditure (2009-2015)
5.2.8 Escalating Aged Population
Table 21: Increasing Global Ageing Population of 60 Years or Older (2000-2030E)
5.3 Challenges & Issues
5.3.1 Rise in Anti-fungal Resistance
5.3.2 Lack of New Anti-Fungal Therapies
5.3.3 Severe Side-Effects of Drugs
Table G: Harsh Side Effects of Anti-Fungal Drugs
5.3.4 High Cost of Drugs
Table H: High Cost of Anti-fungal Drugs
6. Competitive Landscape
6.1 Revenue Comparison
Table 22: Revenue Comparison of Key Players (2015)
6.2 Market Cap Comparison
Table 23: Market Cap Comparison of Key Players (2015)
6.3 Product Comparison
Table I: Major Product Comparison (2015)
7. Company Profiles
7.1 Johnson & Johnson
7.1.1 Business Overview
Table 24: Johnson & Johnson Revenue Share by Business Segments (2015)
7.1.2 Financial Overview
Table 25: Johnson & Johnson Revenue and Net Income (2012-2015)
7.1.3 Business Strategies
Table J: New Innovative Product Portfolio of Johnson & Johnson (2015)
7.2 Novartis AG
7.2.1 Business Overview
Table 26: Novartis Revenue Share by Segments (2015)
7.2.2 Financial Overview
Table 27: Novartis Revenue and Net Income (2012-2015)
7.2.3 Business Strategies
7.3 Pfizer Inc.
7.3.1 Business Overview
Table 28: Pfizer Inc. Revenue Share by Segment (2015)
7.3.2 Financial Overview
Table 29: Pfizer Inc. Revenue and Net Income (2012-2015)
7.3.3 Business Strategies
Table K: New Products of Pfizer with FDA Approval (2015/2016)
7.4 Merck & Co. Inc.
7.4.1 Business Overview
Table 30: Merck & Co. Inc. Revenue Share by Segments
7.4.2 Financial Overview
Table 31: Merck & Co. Inc. Revenue and Net Income (2011-2015)
7.4.3 Business Strategies
Table L: FDA Approvals to Merck & Co. Products (2015/2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report